Autifony Therapeutics Ltd has obtained an additional £8 million in funding to expand the potential for its potassium channel modulator technology beyond hearing disorders, to schizophrenia and other indications. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
